Cover Image

Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China

Background: Tislelizumab, a new high-affinity programmed cell death protein-1 (PD-1) inhibitor, significantly prolonged the overall survival in pretreated non-small-cell lung cancer (NSCLC). This study aimed to assess the cost-effectiveness of tislelizumab versus docetaxel for this population in Chi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jinhong Gong (Author), Dan Su (Author), Jingjing Shang (Author), Shan Xu (Author), Lidan Tang (Author), Zhiqiang Sun (Author), Guangjun Liu (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China
by: Xiaoyu Zhang, et al.
Published: (2024)

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
by: Dongchu Zhou, et al.
Published: (2022)

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
by: Xia Luo, et al.
Published: (2022)

Targeting of non-apoptotic cancer cell death mechanisms by quercetin: Implications in cancer therapy
by: Hao Yang, et al.
Published: (2022)

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
by: Xueyan Liang, et al.
Published: (2023)

Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
by: Zhiwei Zheng, et al.
Published: (2024)

Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials
by: Yimeng Guo, et al.
Published: (2023)

Efficacy and safety of Chinese medicine injections in combination with docetaxel and cisplatin for non-small cell lung cancer: a network meta-analysis
by: Liangtao Wen, et al.
Published: (2023)

Maintenance therapy with oral etoposide following first-line docetaxel-cisplatin chemotherapy in metastatic non-small cell lung cancer patients
by: Meiyu Fang, et al.
Published: (2012)

Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
by: Fenghao Shi, et al.
Published: (2022)

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
by: Zhengda Pei, et al.
Published: (2023)

Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non‐small cell lung cancer
by: Thomas Heineman, et al.
Published: (2021)

Docetaxel-Loaded Novel Nano-Platform for Synergistic Therapy of Non-Small Cell Lung Cancer
by: Xing Feng, et al.
Published: (2022)

Adenosine Conjugated Docetaxel Nanoparticles-Proof of Concept Studies for Non-Small Cell Lung Cancer
by: Hibah M. Aldawsari, et al.
Published: (2022)

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors
by: Nageshwar Budha, et al.
Published: (2023)

Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors
by: Tian Yu, et al.
Published: (2024)

Corrigendum: Docetaxel-loaded novel nano-platform for synergistic therapy of non-small cell lung cancer
by: Xing Feng, et al.
Published: (2022)

Docetaxel-loaded exosomes for targeting non-small cell lung cancer: preparation and evaluation in vitro and in vivo
by: Ying Wang, et al.
Published: (2021)

SINGLE AGENT DOCETAXEL AS SECOND- LINE CHEMOTHERAPY FOR PRETREATED PATIENTS WITH RECURRENT NON- SMALL CELL LUNG CANCER
by: Deyan N. Davidov
Published: (2013)

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China
by: Wenwang Lang, et al.
Published: (2024)

Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
by: Zhou C, et al.
Published: (2023)

Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma
by: Pingyu Chen, et al.
Published: (2024)

Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
by: Yanhong Liu, et al.
Published: (2024)

Zinc supplementation induces apoptosis and enhances antitumor efficacy of docetaxel in non-small-cell lung cancer
by: Kocdor H, et al.
Published: (2015)

Significant Suppression of Non-small-cell Lung Cancer by Hydrophobic Poly(ester amide) Nanoparticles with High Docetaxel Loading
by: Xing Chen, et al.
Published: (2018)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
by: Xiaomin Wan, et al.
Published: (2021)

Effects of Docetaxel Combined with Icotinib on Serum Tumor Markers and Quality of Life of Patients with Advanced Non-Small Cell Lung Cancer
by: Huawei LIN, et al.
Published: (2020)

Trends of Antibiotic Use and Expenditure After an Intensified Antimicrobial Stewardship Policy at a 2,200-Bed Teaching Hospital in China
by: Xiaodan Qian, et al.
Published: (2021)

An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective
by: Alicia K. Morgans, et al.
Published: (2022)

Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report
by: María Espinosa Bosch, et al.
Published: (2016)

A case report: deep and durable response to low-dose lenvatinib and tislelizumab in an elderly patient with advanced intrahepatic cholangiocarcinoma
by: Pei Zhang, et al.
Published: (2024)

Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors
by: Dingwei Ye, et al.
Published: (2023)

Preparation, characterization, and antiproliferative activities of biotin-decorated docetaxel-loaded bovine serum albumin nanoparticles
by: Kai Cheng, et al.
Published: (2018)

Enhanced Lung Cancer Therapy via Co-Encapsulation of Docetaxel and Betulinic Acid
by: Trideep Saikia, et al.
Published: (2024)

PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
by: A. U. Kulikov
Published: (2015)

Histopathological Efficacy of Docetaxel Versus Paclitaxel As First Line Chemotherapy for Epithelial Ovarian Carcinoma
by: Tayyup Şimşek, et al.
Published: (2008)

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
by: Miriam Alonso-García, et al.
Published: (2022)

Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens
by: Li LF, et al.
Published: (2024)

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
by: Qiao Liu, et al.
Published: (2021)

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
by: Ming-kun Chen, et al.
Published: (2022)